Literature DB >> 15047232

Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers.

Kathryn M Burleson1, Rachael C Casey, Keith M Skubitz, Stephan E Pambuccian, Theodore R Oegema, Amy P N Skubitz.   

Abstract

OBJECTIVES: Ovarian carcinoma cells form multicellular aggregates, or spheroids, in the peritoneal cavity of patients with advanced disease. The current paradigm that ascites spheroids are non-adhesive leaves their contribution to ovarian carcinoma dissemination undefined. Here, spheroids obtained from ovarian carcinoma patients' ascites were characterized for their ability to adhere to molecules encountered in the peritoneal cavity, with the goal of establishing their potential to contribute to ovarian cancer spread.
METHODS: Spheroids were recovered from the ascites fluid of 11 patients with stage III or stage IV ovarian carcinoma. Adhesion assays to extracellular matrix (ECM) proteins and human mesothelial cell monolayers were performed for each of the ascites spheroid samples. Subsequently, inhibition assays were performed to identify the cell receptors involved.
RESULTS: Most ascites samples adhered moderately to fibronectin and type I collagen, with reduced adhesion to type IV collagen and laminin. Monoclonal antibodies against the beta1 integrin subunit partially inhibited this adhesion. Ascites spheroids also adhered to hyaluronan. Additionally, spheroids adhered to live, but not fixed, human mesothelial cell monolayers, and this adhesion was partially mediated by beta1 integrins.
CONCLUSIONS: The cellular content of the ascites fluid has often been considered non-adhesive, but our findings are the first to suggest that patient-derived ascites spheroids can adhere to mesothelial extracellular matrix via beta1 integrins, indicating that spheroids should not be ignored in the dissemination of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047232     DOI: 10.1016/j.ygyno.2003.12.034

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  131 in total

1.  Ovarian cancer spheroids use myosin-generated force to clear the mesothelium.

Authors:  Marcin P Iwanicki; Rachel A Davidowitz; Mei Rosa Ng; Achim Besser; Taru Muranen; Melissa Merritt; Gaudenz Danuser; Tan A Ince; Tan Ince; Joan S Brugge
Journal:  Cancer Discov       Date:  2011-07       Impact factor: 39.397

2.  In vitro three-dimensional modelling of human ovarian surface epithelial cells.

Authors:  K Lawrenson; E Benjamin; M Turmaine; I Jacobs; S Gayther; D Dafou
Journal:  Cell Prolif       Date:  2009-04-24       Impact factor: 6.831

Review 3.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

4.  M-Trap: Exosome-Based Capture of Tumor Cells as a New Technology in Peritoneal Metastasis.

Authors:  Alexandre de la Fuente; Lorena Alonso-Alconada; Clotilde Costa; Juan Cueva; Tomas Garcia-Caballero; Rafael Lopez-Lopez; Miguel Abal
Journal:  J Natl Cancer Inst       Date:  2015-07-06       Impact factor: 13.506

5.  Initial formation of IGROV1 ovarian cancer multicellular aggregates involves vitronectin.

Authors:  Sabrina Kellouche; Julien Fernandes; Johanne Leroy-Dudal; Olivier Gallet; Soizic Dutoit; Laurent Poulain; Franck Carreiras
Journal:  Tumour Biol       Date:  2010-02-24

6.  Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.

Authors:  Rachel A Davidowitz; Laura M Selfors; Marcin P Iwanicki; Kevin M Elias; Alison Karst; Huiying Piao; Tan A Ince; Michael G Drage; Judy Dering; Gottfried E Konecny; Ursula Matulonis; Gordon B Mills; Dennis J Slamon; Ronny Drapkin; Joan S Brugge
Journal:  J Clin Invest       Date:  2014-04-24       Impact factor: 14.808

7.  Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.

Authors:  Shreya Raghavan; Maria R Ward; Katelyn R Rowley; Rachel M Wold; Shuichi Takayama; Ronald J Buckanovich; Geeta Mehta
Journal:  Gynecol Oncol       Date:  2015-04-22       Impact factor: 5.482

8.  Stromal interactions as regulators of tumor growth and therapeutic response: A potential target for photodynamic therapy?

Authors:  Jonathan P Celli
Journal:  Isr J Chem       Date:  2012-07-24       Impact factor: 3.333

9.  Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.

Authors:  Elizabeth H Kerr; Peter J Frederick; Michael E Egger; Cecil R Stockard; Jeffery Sellers; Debbie DellaManna; Denise K Oelschlager; Hope M Amm; Isam-Eldin Eltoum; J Michael Straughn; Donald J Buchsbaum; William E Grizzle; Lacey R McNally
Journal:  Ann Surg Oncol       Date:  2013-03-24       Impact factor: 5.344

10.  Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells.

Authors:  Alanna Kennedy; Huan Dong; Donghai Chen; Wen-Tien Chen
Journal:  Int J Cancer       Date:  2009-01-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.